ArticleOncology letters2020

Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.

Chen Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.